About Pricing FAQs Blog

Loading clinical trials...

Clareo Health Find Clinical Trials →

© 2026 Clareo Health. All rights reserved.

COMPLETED

Observational Prospective Study on Patients Treated With Norditropin®

NordiNet® International Outcome Study-Observational Prospective Study on Patients Treated With Norditropin®

NCT00960128•Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

This observational study is conducted globally. The aim of the study is to investigate the effectiveness and safety of real-life treatment with Norditropin®. The study population will consist of children and adults who are on treatment with Norditropin® in accordance with normal clinical practice.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Judged by the physician as per the Norditropin® label

Exclusion Criteria

•Judged by the physician as per the Norditropin® label

Locations (23)

Novo Nordisk Investigational Site

Prov. de Buenos Aires, Argentina

Novo Nordisk Investigational Site

Brussels, Belgium

Novo Nordisk Investigational Site

Prague, Czechia

Novo Nordisk Investigational Site

Copenhagen S, Denmark

Novo Nordisk Investigational Site

Espoo, Finland

Novo Nordisk Investigational Site

Paris La Défense Cedex, France

Novo Nordisk Investigational Site

Mainz, Germany

Novo Nordisk Investigational Site

Budapest, Hungary

Novo Nordisk Investigational Site

Dublin, Ireland

Novo Nordisk Investigational Site

Kfar Saba, Israel

Key Dates

Start Date

April 1, 2006

Primary Completion Date

December 31, 2016

Completion Date

December 31, 2016

Last Updated

October 12, 2017

Enrollment

21,249

ACTUAL participants

Conditions

Growth Hormone DisorderGrowth Hormone Deficiency in ChildrenAdult Growth Hormone DeficiencyGenetic DisorderTurner SyndromeFoetal Growth ProblemSmall for Gestational AgeChronic Kidney DiseaseChronic Renal InsufficiencyNoonan Syndrome

Interventions

somatropin

DRUG

somatropin

DRUG

Sponsors

Lead Sponsor

Novo Nordisk A/S

Related Studies

ENROLLING_BY_INVITATION

Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed

NCT06109935

Growth Hormone Deficiency in Children

ENROLLING_BY_INVITATION

Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®

NCT05230550

Adult Growth Hormone Deficiency

COMPLETEDPHASE3

A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 12, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

NCT04970654

Growth Hormone Deficiency in Children

View study

NOT_YET_RECRUITINGPHASE2

A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)

NCT07259564

Adult Growth Hormone Deficiency (AGHD)

COMPLETEDPHASE1

First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects

NCT01514500

Growth Hormone DisorderAdult Growth Hormone Deficiency+2 more

COMPLETEDPHASE3

A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency

NCT03075644

Growth Hormone DisorderAdult Growth Hormone Deficiency

View all related studies